This is a glioma IDH1R132H mutant isogenic line derived from the parental U-87MG (ATCC® HTB-14) cell line. The c.395G>A knock-in mutation encoding IDH1R132H protein expression was generated at ATCC by utilizing the CRISPR/Cas9 gene editing technology. This is a heterozygous mutation expressing the c.395G>A mutant allele. The IDH1R132H mutation in HTB-14IG has been validated at the genomic, transcript, and protein bio-functional levels.
The IDH1R132H mutation is among the most common seen in glioma and serves as an important diagnostic marker in various stages of disease in patients.
This IDH1R132H mutant isogenic line HTB-14IG has been tested at ATCC for neomorphic functional activity displaying elevated levels of intra- and extracellular D-2HG above the parental U-87MG line. In addition, the HTB-14IG IDH1 mutant isogenic line displays histone hypermethylation compared to the parental line. This IDH1R132H isogenic cell model is a valuable in vitro cell-based tool for clinical diagnostics, elucidating mechanisms involved in cancer-associated differentiation, tumorigenesis and use in screening anti-cancer compounds for drug discovery and development.
Refer to the parental line U-87MG (ATCC® HTB-14) for additional background information.